Blog
RSS FeedPosted by Michael Wonder on 17 Mar 2022
Panel scrutinises quick FDA drug approvals
17 March 2022 - A House committee will spotlight an FDA process that’s been criticised as putting some of the ...
Posted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...
Posted by Michael Wonder on 21 Feb 2022
Responses to Prostheses List reform
16 February 2022 - Consultation paper #3 A modernised fit for purpose listing process was released on 11 January and closes ...
Posted by Michael Wonder on 15 Feb 2022
Office of Generic Drugs 2021 Annual Report
14 February 2022 - Ensuring high quality, affordable generic drugs are available to the American public. ...
Posted by Michael Wonder on 15 Feb 2022
Human medicines: highlights of 2021
15 February 2022 - In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance ...
Posted by Michael Wonder on 14 Feb 2022
EMA starts safety review of Janus kinase inhibitors for inflammatory disorders
11 February 2022 - EMA’s safety committee, PRAC, has started a review of the safety of Janus kinase (JAK) inhibitors ...
Posted by Michael Wonder on 10 Feb 2022
National Medicines Policy too important to be rushed before Federal Election
10 February 2022 - Following consultation with members – and heeding the concerns of the Consumers Health Forum and patient ...
Posted by Michael Wonder on 07 Feb 2022
Review of the National Medicines Policy – consultation on draft National Medicines Policy extended
8 February 2022 - The consultation period on the draft NMP was due to close on Wednesday 16 February 2022. ...
Posted by Michael Wonder on 07 Feb 2022
Medicines Australia calls for new National Medicines Policy to be pushed back until after the federal election
4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...
Posted by Michael Wonder on 02 Feb 2022
ABPI analysis on NICE’s changes for evaluating new medicines: next steps
31 January 2022 - NICE has published a new Manual, which sets out how the latest medicines and health technologies ...
Posted by Michael Wonder on 02 Feb 2022
Review of the National Medicines Policy – consultation on the draft closes 16 February 2022
2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...
Posted by Michael Wonder on 31 Jan 2022
NICE publishes new combined methods and processes manual and topic selection manual for its health technology evaluation programmes
31 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 21 Jan 2022
National Medicines Policy Review – publication of submissions
21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...
Posted by Michael Wonder on 20 Jan 2022
NICE moves: increased accessibility and flexibility for health tech
19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...